Comparison 10. Low versus higher dose target of rapamycin inhibitors (TOR‐ I): secondary outcomes.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 New‐onset diabetes mellitus	6	2125	Risk Ratio (M‐H, Random, 95% CI)	0.69 [0.51, 0.93]
2 Lymphoma/PTLD	7	2792	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.25, 1.73]
3 Adverse cosmetic outcomes	7		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Tremor	1	387	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.63, 1.29]
3.2 Gingival hyperplasia	2	622	Risk Ratio (M‐H, Random, 95% CI)	1.45 [0.48, 4.42]
3.3 Hirsutism	2	1102	Risk Ratio (M‐H, Random, 95% CI)	0.50 [0.30, 0.85]
3.4 Acne/rash	6	2408	Risk Ratio (M‐H, Random, 95% CI)	0.86 [0.62, 1.21]
4 Glomerular filtration rate	7	1863	Mean Difference (IV, Random, 95% CI)	2.88 [‐0.71, 6.48]
5 Serum creatinine	7	1951	Mean Difference (IV, Random, 95% CI)	‐2.21 [‐13.68, 9.26]
6 Elevated lipid levels	9		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 Hypercholesterolaemia	9	3250	Risk Ratio (M‐H, Random, 95% CI)	0.87 [0.78, 0.98]
6.2 Hypertriglyceridaemia	5	1064	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.47, 1.07]
7 Lipid outcomes	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Cholesterol	5	1041	Mean Difference (IV, Random, 95% CI)	‐0.13 [‐0.35, 0.08]
7.2 Triglycerides	4	1041	Mean Difference (IV, Random, 95% CI)	‐0.37 [‐0.72, ‐0.03]
8 Abnormal haematological values	12		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 Anaemia	10	3179	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.72, 0.91]
8.2 Leucopenia	12	3831	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.57, 0.92]
8.3 Thrombocytopenia	9	2242	Risk Ratio (M‐H, Random, 95% CI)	0.58 [0.44, 0.75]
9 Haematological outcomes	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
9.1 Haemoglobin [g/dL]	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
9.2 White cell count [per mm3]	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
9.3 Platelet count [per mm2]	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]